Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Tue, 18-Aug 7:00 AM ET)
Pulse Biosciences Rides Strong Trial Momentum
TipRanks (Sun, 16-Aug 8:16 PM ET)
Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Business Wire (Thu, 6-Aug 4:05 PM ET)
Pulse Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference
Business Wire (Thu, 30-Jul 4:05 PM ET)
Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study
Business Wire (Wed, 29-Jul 7:00 AM ET)
Pulse Biosciences Schedules Second Quarter 2026 Financial Results Conference Call for August 6, 2026
Business Wire (Tue, 21-Jul 4:05 PM ET)
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
Business Wire (Wed, 10-Jun 7:00 AM ET)
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Business Wire (Wed, 27-May 4:05 PM ET)
Market Chameleon (Wed, 4-Mar 3:17 AM ET)
Pulse Biosciences Set to Spotlight Nanosecond Pulsed Field Ablation at Major Healthcare Conference
Market Chameleon (Fri, 20-Feb 3:39 AM ET)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
Pulse Biosciences trades on the NASDAQ stock market under the symbol PLSE.
As of August 18, 2026, PLSE stock price declined to $46.00 with 510,792 million shares trading.
PLSE has a beta of 0.79, meaning it tends to be less sensitive to market movements. PLSE has a correlation of 0.01 to the broad based SPY ETF.
PLSE has a market cap of $3.28 billion. This is considered a Mid Cap stock.
Last quarter Pulse Biosciences reported $434,000 in Revenue and -$.36 earnings per share. This fell short of revenue expectation by $-132,664 and missed earnings estimates by -$.07.
In the last 3 years, PLSE traded as high as $48.10 and as low as $3.78.
The top ETF exchange traded funds that PLSE belongs to (by Net Assets): IWM, VTI, VXF, IWO, SCHA.
PLSE has outperformed the market in the last year with a price return of +184.7% while the SPY ETF gained +20.4%. PLSE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +87.4% and +21.9%, respectively, while the SPY returned +4.1% and +1.3%, respectively.
PLSE support price is $44.27 and resistance is $49.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLSE shares will trade within this expected range on the day.